"Drug King" Adamu single resistance to the fierce rivals: biosimilar AVT02 achieved positive results
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Alvotech Pharmaceuticals announced today that two studies on AVT02 have reached its main goalThe AVT02 is a biosimilar of Humira (Adamu mono-resistant) with a high concentration (100mg/mL) dosage form that is expected to bring more convenience to patients and differentiate it from most biosimilar competitorsas part of the development of AVT02, an important Phase I clinical study has been conducted to compare healthy volunteers with subcutaneous injections of AVT02 and Humira pharmacokinetics (PK)It turns out that AVT02 has similar PK characteristics to Humira (Adamu mono-resistance)another Phase III comparative validation study showed that AVT02 had similar percentage improvement percentages to the 16th week psoriasis area and severity index (PASI) in the HUmira group when treating patients with moderate to severe chronic plaque psoriasis with Humira (Adamu monoantigen)In addition, both studies showed no significant differences in safety, tolerability, and immunogenicity between AVT02 and Humira."
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
